Delivery Order SPE2DB22D3301-SPE2DB25FY2UR

Award Date 4/7/25
Potential Completion Date 4/8/25
Potential Value $2.4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,014.48, is a delivery order under an Indefinite Delivery Contract (IDC) for the supply of OMNIPAQUE 350 MG/ML PLUSPAK 500ML, a medical product. The contract has an ultimate completion date of February 14, 2025 and is a firm fixed-price arrangement. The contract does not have a set-aside...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,141.62, is a delivery order for the medical product "OMNIPAQUE 300 MG/ML PLUSPAK 500ML". The contract has an ultimate completion date of March 11, 2025 and is a firm fixed-price contract. This award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds...
This federal contract award to AmerisourceBergen Drug Corp (a major pharmaceutical distributor) is a delivery order under a $999,999,999 Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical. The order is for the medical product "OMNIPAQUE 350 MG/ML PLUSPAK 500ML" and has a ceiling value of $3,498.20. The contract is a Firm Fixed Price arrangement with an ultimate completion date of October 29, 2024. This contract does not have a set-aside...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA), a defense agency, to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of OMNIPAQUE 350 MG/ML PLUSPAK 500ML, a medical product, with a ceiling value of $1,690.80 and a period of performance ending on June 4, 2025. The contract is not set aside and is awarded on a firm-fixed-price basis. Amerisourcebergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of OMNIPAQUE 350 MG/ML PLUSPAK 500ML, a medical product, with a ceiling value of $1,690.80 and a performance period through May 15, 2025. The contract is a firm fixed-price delivery order and is not set aside for any specific business category. AmerisourceBergen Drug Corp holds a larger...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,690.80 firm fixed-price delivery order is for the medical product "OMNIPAQUE 350 MG/ML PLUSPAK 500ML" and has an ultimate completion date of January 22, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,690.80 contract is for the delivery of OMNIPAQUE 350 MG/ML PLUSPAK 500ML, a medical product. The contract has a completion date of June 16, 2025 and is not designated as a set-aside. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of OMNIPAQUE 350 MG/ML PLUSPAK 500ML, a pharmaceutical product, with a ceiling value of $2,011.96 and a period of performance through April 29, 2025. The contract is a firm fixed-price delivery order, without any set-aside designation, indicating open competition....
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distribution and healthcare solutions provider. The contract, valued at $1,399.28, is for the supply of OMNIPAQUE 350 MG/ML PLUSPAK 500ML, a medical product used in healthcare settings. The contract has a firm fixed-price pricing structure and a completion date of June 5, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,809.50 firm fixed-price contract is for the delivery of OMNIPAQUE 300 MG/ML PLUSPAK 500ML, a medical product used in healthcare settings. The contract has an ultimate completion date of November 1, 2024 and was awarded on October 31, 2024. This delivery order is part of a larger Indefinite Delivery...
  • SPE2DB22D3301
    Indefinite Delivery Contract
  • SPE2DB22D3301-SPE2DB25FY2UR
    Delivery Order

This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of OMNIPAQUE 350 MG/ML PLUSPAK 500ML, a medical supply item, with a ceiling value of $2,367.12 and a period of performance through April 8, 2025. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The current award does not have a set-aside designation, indicating open competition.

Generated 7/7/25, 1:12 PM